[Cancer Research 55, 3228-3232, August 1, 1995]
© 1995 American Association for Cancer Research
Gelsolin: A Candidate for Suppressor of Human Bladder Cancer1
Motoyoshi Tanaka,
Leonhard Müllauer2,
Yoshifumi Ogiso,
Hisakazu Fujita,
Shingo Moriya,
Keiji Furuuchi,
Tohru Harabayashi,
Nobuo Shinohara,
Tomohiko Koyanagi and
Noboru Kuzumaki3
Laboratory of Molecular Genetics, Cancer Institute [M. T., L. M., Y. O., H. F., S. M., K. F., N. K.], Department of Urology [M. T., T. H., N. S., T. K.], Hokkaido University School of Medicine, Kita-15, Nishi-7 Kita-ku, Sapporo 060, Japan
Human transitional cell carcinomas of the bladder frequently reveal chromosomal abnormalities that span a range between chromosome 9p12 and 9qter, even at early stages of bladder carcinogenesis. Because the gene that encodes an actin-regulatory protein, gelsolin, is localized in chromosome 9q33, we examined the expression of gelsolin in a number of human bladder cancer cell lines and tissues. In all 6 cell lines and in 14 of the 18 tumor tissues (77.8%), gelsolin expression was undetectable or extremely low in comparison with its expression in normal bladder epithelial cells. Furthermore, upon the introduction of the exogenous human or mouse authentic gelsolin cDNA into a human bladder cancer cell line, UMUC-2, gelsolin transfectants of UMUC-2 greatly reduced the colony-forming ability and the tumorigenicity in vivo. These results suggest that gelsolin plays a key role as a tumor suppressor in human urinary bladder carcinogenesis.
1 This work was supported in part by a grant-in-aid from the Ministry of Education, Science and Culture, Japan.
2 Present address: Institute of Clinical Pathology, University of Vienna, Vienna, Austria.
3 To whom requests for reprints should be addressed.
Received 3/ 7/95.
Accepted 6/15/95.
This article has been cited by other articles:
|
|
|
|
 
M. Sanchez-Carbayo, N. D. Socci, L. Richstone, M. Corton, N. Behrendt, J. Wulkfuhle, B. Bochner, E. Petricoin, and C. Cordon-Cardo
Genomic and Proteomic Profiles Reveal the Association of Gelsolin to TP53 Status and Bladder Cancer Progression
Am. J. Pathol.,
November 1, 2007;
171(5):
1650 - 1658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Kim, F. Furuya, H. Ying, Y. Kato, J. A. Hanover, and S.-y. Cheng
Gelsolin: A Novel Thyroid Hormone Receptor-{beta} Interacting Protein that Modulates Tumor Progression in a Mouse Model of Follicular Thyroid Cancer
Endocrinology,
March 1, 2007;
148(3):
1306 - 1312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C C Thompson, F J Ashcroft, S Patel, G Saraga, D Vimalachandran, W Prime, F Campbell, A Dodson, R E Jenkins, N R Lemoine, et al.
Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility
Gut,
January 1, 2007;
56(1):
95 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Sjoblom, S. Jones, L. D. Wood, D. W. Parsons, J. Lin, T. D. Barber, D. Mandelker, R. J. Leary, J. Ptak, N. Silliman, et al.
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Science,
October 13, 2006;
314(5797):
268 - 274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Jin, K. K. Iwata, A. Belldegrun, R. Figlin, A. Pantuck, Z.-F. Zhang, R. Lieberman, and J. Rao
Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model.
Mol. Cancer Ther.,
July 1, 2006;
5(7):
1754 - 1763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. K. Mukhopadhyay, E. Weisberg, D. Gilchrist, R. Bueno, D. J. Sugarbaker, and M. T. Jaklitsch
Effectiveness of Trichostatin A as a Potential Candidate for Anticancer Therapy in Non-Small-Cell Lung Cancer.
Ann. Thorac. Surg.,
March 1, 2006;
81(3):
1034 - 1042.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q.-Y. Lu, Y.-S. Jin, A. Pantuck, Z.-F. Zhang, D. Heber, A. Belldegrun, M. Brooks, R. Figlin, and J. Rao
Green Tea Extract Modulates Actin Remodeling via Rho Activity in an In vitro Multistep Carcinogenic Model
Clin. Cancer Res.,
February 15, 2005;
11(4):
1675 - 1683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rahman, H. Miyamoto, and C. Chang
Androgen Receptor Coregulators in Prostate Cancer: Mechanisms and Clinical Implications
Clin. Cancer Res.,
April 1, 2004;
10(7):
2208 - 2219.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Nishimura, H.-J. Ting, Y. Harada, T. Tokizane, N. Nonomura, H.-Y. Kang, H.-C. Chang, S. Yeh, H. Miyamoto, M. Shin, et al.
Modulation of Androgen Receptor Transactivation by Gelsolin: A Newly Identified Androgen Receptor Coregulator
Cancer Res.,
August 15, 2003;
63(16):
4888 - 4894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. O. Hoque, C.-C. R. Lee, P. Cairns, M. Schoenberg, and D. Sidransky
Genome-Wide Genetic Characterization of Bladder Cancer: A Comparison of High-Density Single-Nucleotide Polymorphism Arrays and PCR-based Microsatellite Analysis
Cancer Res.,
May 1, 2003;
63(9):
2216 - 2222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Lim, I. Han, H. J. Kwon, and E.-S. Oh
Trichostatin A-induced Detransformation Correlates with Decreased Focal Adhesion Kinase Phosphorylation at Tyrosine 861 in ras-transformed Fibroblasts
J. Biol. Chem.,
April 5, 2002;
277(15):
12735 - 12740.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.-H. Chang and E. Szabo
Enhanced Growth Inhibition by Combination Differentiation Therapy with Ligands of Peroxisome Proliferator-activated Receptor-{gamma} and Inhibitors of Histone Deacetylase in Adenocarcinoma of the Lung
Clin. Cancer Res.,
April 1, 2002;
8(4):
1206 - 1212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. Koya, H. Fujita, S. Shimizu, M. Ohtsu, M. Takimoto, Y. Tsujimoto, and N. Kuzumaki
Gelsolin Inhibits Apoptosis by Blocking Mitochondrial Membrane Potential Loss and Cytochrome c Release
J. Biol. Chem.,
May 12, 2000;
275(20):
15343 - 15349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.-H. Chang and E. Szabo
Induction of Differentiation and Apoptosis by Ligands of Peroxisome Proliferator-activated Receptor {{gamma}} in Non-Small Cell Lung Cancer
Cancer Res.,
February 1, 2000;
60(4):
1129 - 1138.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Saito, T. Yamashita, Y. Mariko, Y. Nosaka, K. Tsuchiya, T. Ando, T. Suzuki, T. Tsuruo, and O. Nakanishi
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors
PNAS,
April 13, 1999;
96(8):
4592 - 4597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Klampfer, J. Cammenga, H.-G. Wisniewski, and S. D. Nimer
Sodium Salicylate Activates Caspases and Induces Apoptosis of Myeloid Leukemia Cell Lines
Blood,
April 1, 1999;
93(7):
2386 - 2394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Takaoka, T. Yamada, M. Gotoh, Y. Kanai, K. Imai, and S. Hirohashi
Cloning and Characterization of the Human beta 4-Integrin Gene Promoter and Enhancers
J. Biol. Chem.,
December 11, 1998;
273(50):
33848 - 33855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Robbens, J. Louahed, K. De Pestel, I. Van Colen, C. Ampe, J. Vandekerckhove, and J.-C. Renauld
Murine Adseverin (D5), a Novel Member of the Gelsolin Family, and Murine Adseverin Are Induced by Interleukin-9 in T-Helper Lymphocytes
Mol. Cell. Biol.,
August 1, 1998;
18(8):
4589 - 4596.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H. J. Kwon, T. Owa, C. A. Hassig, J. Shimada, and S. L. Schreiber
Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase
PNAS,
March 31, 1998;
95(7):
3356 - 3361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kothakota, T. Azuma, C. Reinhard, A. Klippel, J. Tang, K. Chu, T. J. McGarry, M. W. Kirschner, K. Koths, D. J. Kwiatkowski, et al.
Caspase-3-Generated Fragment of Gelsolin: Effector of Morphological Change in Apoptosis
Science,
October 10, 1997;
278(5336):
294 - 298.
[Abstract]
[Full Text]
|
|
|
Copyright © 1995 by the American Association for Cancer Research.
